This is actually the first NLRP3 inhibitor medical trial in Parkinson’s so it will be exciting to check out what Roche finds in their knowledge. Other (unbiased) research teams have also claimed increased amounts of NLRP3 within the dopamine neurons of those with Parkinson’s. For example: Scientific profile of sufferers https://fedratinib55421.anchor-blog.com/8613677/bi-2852-no-further-a-mystery